Cipla's scion leaves company for 'new horizons'
This article was originally published in Scrip
Executive Summary
Cipla's scion Kamil Hamied, son of vice-chair MK Hamied and nephew of chairman, Dr Yusuf Hamied, is leaving the Indian generic giant.
You may also be interested in...
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, an investment banker tells Scrip.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.